Mainz Biomed (MYNZ) Provides Year-End 2022 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Mainz Biomed Provides Year-End 2022 Corporate Review
January 3, 2023 3:01 AM ESTBERKELEY, US and MAINZ, Germany , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a corporate summary for the fiscal year ended December 31, 2022.
Key Commercial, Operational and Product Development Highlights
Launched U.S.-based eAArly DETECT study by enrolling the first patient; study focused on the performance of Mainz Biomeds mRNA biomarkers in identifying Advance Adenomas (AA), a type of pre-cancerous polyp often attributed to... More